Skip To Main Content
Asher Mullard on Muck Rack

Asher Mullard

Verified
Ottawa
As seen in: Nature Biotechnology, British Journal of Cancer, Nature, Nature Reviews Drug Discovery, Scientific American, ACS Publications, Chemical & Engineering News (C&EN), Flipboard, STAT, The Lancet, Genetic Literacy Project and
Freelance science journalist, covering drugs, clinical trials, biotech, pharma and more. Writes for Nature, The Lancet, The New Scientist, and others.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Asher

Contact Asher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Oral macrocyclic PCSK9 inhibitor secures FDA approval

|
By Asher Mullard Verified
| Nature Verified
NEWS IN BRIEF 30 July 2026 Merck & Co.’s enlicitide (Lipfendra) has been approved as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The company expects the orally available macrocycle to provide a convenience advantage over other PCSK9-targeted alternatives.
Open in Who Shared Issue with article?

CAR T cell therapy for solid cancer scores first approval in China

|
By Asher Mullard Verified
| Flipboard
0:22 11 hours ago India: Leopard strikes biker during sudden entry into residential area, massive search operation underway. StringersHub • 11h Occurred on July 7, 2026 / Indore, Madhya Pradesh, India. Info: A motorcyclist had a narrow escape after coming under attack from a leopard inside a residential area late at night. The shocking incident left residents alarmed and prompted authorities to launch an immediate search for the wild animal.
Open in Who Shared View Duplicates (25) Issue with article?

FDA approves second IGF-1R-targeted antibody for thyroid eye disease

|
By Asher Mullard Verified
| Nature Verified
NEWS IN BRIEF 08 July 2026 Viridian Therapeutics has secured FDA approval for its IGF-1R-targeted veligrotug (Lumvoa) for thyroid eye disease. The newly approved antibody will compete with Amgen’s first-in-class anti-IGF-1R antibody teprotumumab (Tepezza), potentially by providing a convenience edge over its predecessor.
Open in Who Shared View Duplicates (3) Issue with article?
See all 518 licensed articles (521 Total)